Humira is a prescription drug used to treat hidradenitis suppurativa (HS). Learn how the drug works, who it’s used for, and more.

The Food and Drug Administration (FDA) has designated Hadlima™ (adalimumab-bwwd) an interchangeable biosimilar to Humira ® (adalimumab). Hadlima, a tumor necrosis factor (TNF) blocker, is ...

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance. Click here to read why CVS is a Hold.

With Humira's high cost — more than $8,000 per month, due to the complex biologic process used to make it — employers must find ways to manage costs without compromising patient care.

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

Based on these legal threats, some large employers have switched from traditional PBMs to newer upstarts. 9 Over the course of 2025, more employers are expected to move to more transparent PBM models.

Skyrizi (risankizumab-rzaa) has taken the sales crown away from Humira (reference adalimumab) for the first time, just under 2 years after the first biosimilar to Humira entered the US market, ...

Suppose further research confirms that the transparent model consistently produces savings without sacrificing safety and efficacy. In that case, market forces will force even the largest PBMs and ...

EAGAN, Minn., Oct. 7, 2024 /PRNewswire/ -- Prime Therapeutics LLC (Prime) today announced new, cost-effective Humira biosimilar solutions, offering clients continued flexibility and choice, along with ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the ...

Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025.

Pharma companies have a history of offering funding and other resources that have been shown to influence health-care professionals. (Shutterstock) Some groups that take drug company money do not ...